Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21767595 | 1.00 | PTGDR2 (0.40) | PTGDR2TSHRCYP1A2GAACYP2C9 | |
| SCHEMBL21767407 | 1.00 | PTGDR2 (0.40) | PTGDR2TSHRCYP1A2GAACYP2C9 | |
| SCHEMBL31072015 | 0.85 | CFTR (0.42) | CYP1A2GAACYP2C9HPGDCYP2C19 | |
| SCHEMBL29429452 | 0.85 | CFTR (0.42) | CYP1A2GAACYP2C9HPGDCYP2C19 | |
| SCHEMBL21767420 | 0.85 | CFTR (0.42) | CYP1A2GAACYP2C9HPGDCYP2C19 | |
| SCHEMBL21767551 | 0.85 | CFTR (0.42) | CYP1A2GAACYP2C9HPGDCYP2C19 | |
| SCHEMBL21780595 | 0.85 | CFTR (0.42) | CYP1A2GAACYP2C9HPGDCYP2C19 | |
| SCHEMBL31071934 | 0.85 | CFTR (0.42) | CYP1A2GAACYP2C9HPGDCYP2C19 | |
| SCHEMBL21767410 | 0.81 | CFTR (0.45) | CYP1A2GAACYP2C9HPGDCYP2C19 | |
| SCHEMBL31071992 | 0.81 | CFTR (0.45) | CYP1A2GAACYP2C9HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11021480-B2 | Inhibiting (α-V)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200385384-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | SCHRÖDINGER, LLC | 2020-12-10 | — | — | US | disclosed |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2020047239-A1 | INHIBITING αV β6 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| EP-3617206-A1 | INTEGRIN INHIBITORS | Morphic Therapeutic, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PTGDR2 1758/4885TSHR 2465/4885CYP1A2 4753/4885 |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PTGDR2 1758/4885TSHR 2465/4885CYP1A2 4753/4885 |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PTGDR2 1758/4885TSHR 2465/4885CYP1A2 4753/4885 |
| US-20200385384-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PTGDR2 1758/4885TSHR 2465/4885CYP1A2 4753/4885 |
| US-11021480-B2 | Inhibiting (α-V)(β-6) integrin | ITGB6, ITGA6, ITGAV | PTGDR2 2222/4885TSHR 2291/4885CYP1A2 4794/4885 |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | PTGDR2 2222/4885TSHR 2291/4885CYP1A2 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.